Previous 10 | Next 10 |
2024-01-17 07:52:49 ET More on Gilead, Arcus Biosciences, etc. Gilead Sciences, Inc. (GILD) JPMorgan 42nd Annual Healthcare Conference (Transcript) Gilead's Dividend Growth Potential Looks Phenomenal Without A Clear Growth Path, Gilead Sciences Is A Hold Gile...
2024-01-17 04:20:00 ET Summary The beginning of every month is exciting for all dividend income investors as we look back at the previous month and see how much passive dividend income our portfolios generated. Looking back at my December totals, I see that my year-over-year progr...
2024-01-16 10:50:09 ET Summary Investors are monitoring the S&P 500 stocks as the index starts the year with a pullback and uncertainty over interest rate cuts. Top-performing stocks include Juniper, Nvidia, Eli Lilly, Viatris, and Organon, while solar energy stocks and Boeing...
NORTHAMPTON, MA / ACCESSWIRE / January 16, 2024 / "It's an experience that I hope no one goes through, but it's an empowering experience." When Emma was diagnosed with breast cancer, she felt "pushed aside" due to her age. Hear more about how she advocated for herself with the support of her fa...
2024-01-15 09:40:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-01-14 12:00:24 ET More on CRISPR, GSK, etc. Pfizer Is Part Of The 2024 Healthcare Sector Rally Cohort Impact Of Gene Therapies And Casgevy On Crispr AG And The Industry CRISPR Therapeutics AG (CRSP) 42nd Annual J.P. Morgan Healthcare Conference (Transcript) ...
2024-01-11 15:25:32 ET Summary Sana Biotechnology, Inc. raised $600m in one of the largest-ever biotech IPOs. The company's share price had deteriorated from $25, to <$3, as its in vivo and ex-vivo allogeneic therapies made slow progress or were discarded. Sana now has two ...
2024-01-11 12:14:06 ET More on Health Care Select Sector SPDR XLV Likely Back To Outperforming XLV: Considering The Low-Maintenance Option To Navigate The Healthcare Sector Ideal Pairs Trade Into 2024: Health Vs. Hype: Capitalizing On A Therapeutic Turn And A Tech Tu...
2024-01-10 14:00:24 ET More on Gilead Sciences Gilead Sciences, Inc. (GILD) JPMorgan 42nd Annual Healthcare Conference (Transcript) Gilead's Dividend Growth Potential Looks Phenomenal Without A Clear Growth Path, Gilead Sciences Is A Hold Gilead in 2024: What...
2024-01-10 13:17:03 ET Summary Our 3-step process focuses on wide-moat stocks (as per Morningstar’s rating). We are only interested in those targets that are attractively valued in historical comparison. We share the heat map of the most investable candidates that may b...
News, Short Squeeze, Breakout and More Instantly...
Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its second quarter 2024 financial results and guidance will be released on Thursday, August 8, 2024, after the market closes. At 4:30 p.m. Eastern Time that day, Gilead’s management will host a webcast to discuss the company’...
– New 5-Year Clinical and Real-World Data Reinforce Biktarvy ® as a Long-Term Treatment Option for a Diverse Range of People with HIV, Including Those with Comorbidities – – Investigational, Once-Daily, Once-Weekly and Twice-Yearly Dosing Frequenc...
– PURPOSE 1 Data Showed Zero Infections and 100% Efficacy and Superiority of Lenacapavir to Background HIV Incidence and Daily Truvada ® for PrEP – – If Approved, Lenacapavir Would be the First and Only Twice-Yearly PrEP Choice and Could Address C...